The latest call
FetchingTempus AI, Inc. reported on November 2, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
$71.57-5.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026
Tempus sells genetic tests ordered by doctors for cancer patients, with insurers or patients paying, and licenses health data to drug companies.
Company outlook: revenue of $1.6B to $1.6B for Fiscal year 2026 — up 26.0% on a year earlier
Just reported
From Tempus AI, Inc.'s results release of November 2, 2026; its quarterly report has since been filed.
Actual
$411.5M
+23% y/y
+7.6% q/q
Guided
—
No guide given
Actual
-$0.08
Guided
—
No guide given
Actual
-$56.9M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $411.5M | $334.2M | +23.14% |
| Profit | -$14.9M | -$80M | +81.43% |
| Profit per share | -$0.08 | -$0.46 | +82.61% |
| Free Cash Flow | -$122K | -$126.5M | +99.90% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Tempus AI, Inc. reported on November 2, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, Tempus is building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Tempus AI, Inc.’s Item 2.02 8-K filed November 2, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.